

Novo Nordisk

The nightmare before Christmas

- Santa left coal in Novo's CagriSema stocking
- But the stock remains an obesity gem
- 22x '25e P/E and a 35% discount to Lilly: BUY

We are both disappointed and encouraged

We were underwhelmed by the 22.7% weight loss, which was below the firm communicated target of ~25%. But we were mostly disappointed by the large effect on patient behaviour in the trial from the implementation of a flexible study design and Novo's surprise at this effect. We do not yet know why only 57% of patients went for the highest CagriSema dose, but we hypothesise that with 40.4% of patients achieving +25% weight loss at an average weight of 106.9 kg to start with, chasing additional weight loss proved a moot point for many patients. We see no indication of side effects in the trial. We are encouraged to note that the 40.4% +25% weight loss compares favourably to highest dose Zepbound, which in the SURMOUNT-1 trial showed 39.7% of patients achieving +25% weight loss.

CagriSema still looks like an approvable drug

The 20% share price drop looks overly aggressive, as CagriSema still looks like an approvable product, having statistically significant Phase 3 data, a better weight loss profile than Wegovy, low patient discontinuation rates and well tolerated side effects. We see CagriSema having a commercial profile at least on a par (possibly better) with Zepbound, and with the high-dose CagriSema subgroup data yet to come. The H2'25 head-2-head trial with Zepbound will be key to the relative commercial strength.

P/E 22x 2025e? No!.....

We implement Catalent but only make small changes to CagriSema 2025-27 estimates. However, in our obesity market model, we lower GLP-1+Amylin's product market share to 15% by 2031e (prev: 20%), which leads to ~6% lower 2031e organic group sales and ~12% lower EBIT. Therefore, we lower our TP to DKK 1,000 (1,100). We reiterate BUY as a 22x '25e P/E and a ~35% discount to Lilly price Novo as a lump of coal, while it still remains an obesity gem.

Analyst: morten.larsen@abgsc.dk, +45 35 46 30 13

DKKm	2022	2023	2024e	2025e	2026e
Sales	176,954	232,261	287,053	349,514	394,371
EBITDA	82,171	111,987	143,988	171,961	195,411
EBITDA margin (%)	46.4	48.2	50.2	49.2	49.6
EBIT adj.	75,569	103,988	127,786	152,234	173,152
EBIT adj. margin (%)	42.7	44.8	44.5	43.6	43.9
Pretax profit	69,062	104,674	125,665	147,690	169,049
EPS	24.51	18.67	22.42	26.51	30.59
EPS adj.	24.78	18.92	22.60	26.74	30.85
Sales growth (%)	25.7	31.3	23.6	21.8	12.8
EPS growth (%)	17.9	-23.8	20.1	18.3	15.4

Source: ABG Sundal Collier, Company Data

Reason: Estimate changes

BUY ● HOLD ○ SELL ○

Healthcare

Estimate changes (%)

	2024e	2025e	2026e
Sales	0.0	-1.5	-2.4
EBIT	0.0	-4.9	-4.8
EPS	-0.8	-7.5	-6.8

Source: ABG Sundal Collier

NOVO.B-DK/NOVOB DC

Share price (DKK)	20/12/2024	589.20
Target price	(1,100.0)	1,000.0

MCap (DKKm)	2,630,778
MCap (EURm)	267,785
No. of shares (m)	3,390.1
Free float (%)	92.9
Av. daily volume (k)	5,597

Next event Q4 Report 5 February 2025

Performance



	2024e	2025e	2026e
P/E (x)	26.3	22.2	19.3
P/E adj. (x)	26.1	22.0	19.1
P/BVPS (x)	19.23	13.42	11.17
EV/EBITDA (x)	18.8	15.6	13.5
EV/EBIT adj. (x)	21.2	17.6	15.3
EV/sales (x)	9.45	7.67	6.71
ROE adj. (%)	83.0	71.9	63.7
Dividend yield (%)	2.3	2.6	0.0
FCF yield (%)	-0.6	3.4	4.3
Le. adj. FCF yld. (%)	-0.6	3.4	4.3
Net IB debt/EBITDA (x)	0.6	0.3	0.2
Le. adj. ND/EBITDA (x)	0.6	0.3	0.2

Company description

Novo Nordisk is a global healthcare company with close to 100 years of innovation and leadership in diabetes care. Headquartered in Denmark, Novo Nordisk employs more than 42,000 people in 80 countries, and markets its products in more than 170 countries. More than 30 million patients use Novo Nordisk's products. Beyond its leadership position in diabetes care, Novo Nordisk also develops and markets therapeutics for serious chronic diseases such as obesity, haemophilia, growth hormone disorders and various cardiovascular diseases.


[Sustainability information](#)

Risks

Pricing pressure from, e.g., increased political pressure due to increasing healthcare expenditure or from commoditisation of science and biosimilar competition. Macroeconomic and geopolitical unrest, especially in emerging markets, as well as changes to the regulatory landscape across key geographies, e.g., in terms of patent exclusivity and approval processes.

CagriSema vs. Zepbound:
 1) CagriSema showed 22.7% weight loss at 68 weeks against placebo showing a 2.3pp effect, for a 20.4% placebo-adjusted effect. This compares favorably to the 22.5% and 2.4pp effect seen for the highest-dose 15mg Tirzepatide in the SURMOUNT-1 trials (Chart B on the right). 2) However, we apply the more stringent treatment regimen estimand approach, under which CagriSema showed 20.4% weight loss (17.4% adjusting for placebo), which is slightly below 15mg Tirzepatide at 20.9% (17.8% placebo-adjusted). 3) Novo reported 40.4% of patients achieving +25% weight loss (39.5% placebo-adjusted), which is in line with the 39.7% delivered by Tirzepatide 15mg (39.4% placebo-adjusted).

Exhibit 1 - Eli Lilly's Tirzepatide SURMOUNT-1 data



Source: New England Journal of Medicine "Tirzepatide Once Weekly for the Treatment of Obesity". Published June 4 2022

Table 1 - Changes to ABGSC Novo Nordisk estimates

(DKK)m)	NEW				OLD				CHANGE			
	2024e	2025e	2026e	2027e	2024e	2025e	2026e	2027e	2024e	2025e	2026e	2027e
Sales	287,053	349,514	394,371	451,585	287,053	354,666	404,223	464,325	0%	-1%	-2%	-3%
<i>Growth, reported</i>	23.6%	21.8%	12.8%	14.5%	23.6%	23.6%	14.0%	14.9%	0.0%p	-1.8%p	-1.1%p	-0.4%p
<i>Growth, local currency</i>	24.1%	19.0%	12.7%	14.3%	24.1%	23.5%	13.8%	14.6%	0.0%p	-4.5%p	-1.1%p	-0.4%p
Insulin (diabetes)	51,759	51,020	51,400	52,636	51,759	49,622	50,044	51,310	0%	3%	3%	3%
Long-acting insulin	18,051	17,521	18,746	20,487	18,051	17,034	18,274	20,026	0%	3%	3%	2%
Premix insulin	10,353	10,805	10,861	11,131	10,353	10,525	10,584	10,849	0%	3%	3%	3%
Fast-acting insulin	16,558	16,393	15,807	15,212	16,558	15,946	15,376	14,798	0%	3%	3%	3%
Human insulin	6,797	6,300	5,985	5,806	6,797	6,117	5,811	5,637	0%	3%	3%	3%
GLP-1 (diabetes)	147,668	165,147	179,275	193,647	147,668	167,634	184,760	199,901	0%	-1%	-3%	-3%
Victoza	5,155	2,201	1,101	550	5,155	2,578	1,547	1,160	0%	-15%	-29%	-53%
Ozempic	119,169	134,303	145,048	155,926	119,169	137,044	150,749	162,055	0%	-2%	-4%	-4%
Rybelsus	23,344	28,643	32,939	36,233	23,344	28,013	32,214	35,436	0%	2%	2%	2%
CagriSema (diabetes)			188	938			250	1,250			-25%	-25%
Obesity	67,599	109,347	138,376	179,332	67,599	113,950	144,653	187,697	0%	-4%	-4%	-4%
Saxenda	6,636	3,166	1,899	1,330	6,636	3,318	2,489	1,991	0%	-5%	-24%	-33%
Wegovy	60,962	105,282	131,602	164,503	60,962	109,732	137,165	171,456	0%	-4%	-4%	-4%
CagriSema (obesity)			375	2,250			500	3,000			-25%	-25%
Diabetes & Obesity (total)	269,152	327,592	371,067	427,611	269,152	333,227	381,418	440,848	0%	-2%	-3%	-3%
Biopharm	17,901	21,922	23,304	23,974	17,901	21,439	22,805	23,478	0%	2%	2%	2%
Haemophilia	11,724	12,226	12,396	12,610	11,724	11,909	12,076	12,286	0%	3%	3%	3%
Growth Hormone	4,584	7,917	8,708	8,247	4,584	7,793	8,572	8,119	0%	2%	2%	2%
Gross profit	243,134	290,097	329,300	379,332	243,134	300,402	342,377	395,605	0%	-3%	-4%	-4%
<i>Gross margin</i>	84.7%	83.0%	83.5%	84.0%	84.7%	84.7%	84.7%	85.2%	0.0%p	-1.7%p	-1.2%p	-1.2%p
Sales & Distribution costs	(64,587)	(80,388)	(90,705)	(101,607)	(64,587)	(81,573)	(92,971)	(104,473)	0%	-1%	-2%	-3%
<i>% of sales</i>	22.5%	23.0%	23.0%	22.5%	22.5%	23.0%	23.0%	22.5%	0.0%p	0.0%p	0.0%p	0.0%p
Research & Development costs	(45,929)	(52,427)	(60,142)	(67,738)	(45,929)	(53,200)	(61,644)	(69,649)	0%	-1%	-2%	-3%
<i>% of sales</i>	16.0%	15.0%	15.3%	15.0%	16.0%	15.0%	15.3%	15.0%	0.0%p	0.0%p	0.0%p	0.0%p
Administrative costs	(5,454)	(6,291)	(6,704)	(7,451)	(5,454)	(6,384)	(6,872)	(7,661)	0%	-1%	-2%	-3%
<i>% of sales</i>	1.9%	1.8%	1.7%	1.7%	1.9%	1.8%	1.7%	1.7%	0.0%p	0.0%p	0.0%p	0.0%p
Licence fees etc.	(400)	0	0	0	(400)	(400)	(400)	(400)	0%	-100%	-100%	-100%
EBIT	126,765	150,990	171,749	202,536	126,765	158,845	180,490	213,422	0%	-5%	-5%	-5%
<i>EBIT margin</i>	44.2%	43.2%	43.6%	44.9%	44.2%	44.8%	44.7%	46.0%	0.0%p	-1.6%p	-1.1%p	-1.1%p
<i>Growth, reported</i>	23.6%	19.1%	13.7%	17.9%	23.6%	25.3%	13.6%	18.2%	0.0%p	-6.2%p	0.1%p	-0.3%p
<i>Growth, local currency</i>	25.0%	19.1%	13.7%	17.9%	25.0%	25.3%	13.6%	18.2%	0.0%p	-6.2%p	0.1%p	-0.3%p
Net financials	(1,100)	(3,300)	(2,700)	(2,450)	(100)	(300)	(300)	(300)	1000%	1000%	800%	717%
Profit before income taxes	125,665	147,690	169,049	200,086	126,665	158,545	180,190	213,122	-1%	-7%	-6%	-6%
Tax	(25,761)	(29,538)	(33,810)	(40,017)	(25,966)	(31,709)	(36,038)	(42,624)	-1%	-7%	-6%	-6%
<i>Tax rate</i>	20.5%	20.0%	20.0%	20.0%	20.5%	20.0%	20.0%	20.0%	0.0%p	0.0%p	0.0%p	0.0%p
Net profit	99,903	118,152	135,239	160,069	100,698	126,836	144,152	170,497	-1%	-7%	-6%	-6%


Source: ABG Sundal Collier

Table 2 - Novo Nordisk 2024 guidance vs expectations

	31-Jan-24 Guidance	02-May-24 Guidance	07-Aug-24 Guidance	06-Nov-24 Guidance	2024e ABGSC
Sales growth					
Constant Exchange Rate (CER)	18-26%	19-27%	22-28%	23-27%	24.1%
Reported	1pp below CER	Inline w. CER	1pp lower	1pp lower	23.6%
EBIT growth					
Constant Exchange Rate (CER)	21-29%	22-30%	20-28%	21-27%	25.0%
Reported	2pp below CER	Inline w. CER	1pp lower	2pp lower	23.6%
Net Financials	1300	-700	-500	-100	-1100
Tax rate	19-21%	19-21%	19-21%	20-21%	20.5%
Capex	45	45	~45	~45	45.0
Depreciation, Amortization and impairment losses	10	10	~17	~17	17.2
Free cash flow (ex. Business development)	64-74	57-67	59-69	57-65	-17

Source: Company collected Consensus

Chart 1 - Novo Nordisk 12 month forward P/E valuation vs peers (Consensus)



Source: FactSet

Exhibit 2 - Novo Nordisk pipeline newsflow

Project	Q3 2024			Q4 2024		H1 2025	
	Clinical milestones ¹			Regulatory milestones ¹		Regulatory milestones ¹	
Diabetes care	FLOW (CKD, Sema 1.0 mg)	✓ CN submission					EU/US decision
	IcoSema				EU (✓) / CN submission		JP submission
	STRIDE (PAD, Sema 1.0 mg)	✓ Phase 3 results					US/EU/CN/JP submission
	SOUL (CVOT, Oral sema 14 mg)				✓ Phase 3 results		US/EU submission
	Monlunabant (INV-202) (DKD)				Phase 2 results		
	Amycretin	✓ Phase 2 initiation					
Obesity care	STEP HFpEF (Sema 2.4 mg)	✓ EU positive opinion					US resubmission
	STEP 9 (OA) (Sema 2.4 mg)				✓ EU positive opinion		
	STEP UP (Sema 7.2 mg)				Phase 3 results		
	CagriSema				Phase 3 results (REDEFINE 1)		Phase 3 results (REDEFINE 2)
	Monlunabant (INV-202)	✓ Phase 2 results					
	Amycretin s.c.						Phase 1 results
	Amylin 355	✓ Phase 1 initiation					
Rare Disease	Mim8				✓ Phase 3 results (FRONTIER 5)		
	Etavopivat SCD	✓ Phase 2 results (interim)					
	Inno8	✓ Phase 1 initiation					
CETA	ESSENCE (MASH, Sema 2.4 mg)				✓ Phase 3 results		US/EU submission

Source: Novo Nordisk

Table 3 - Novo Nordisk quarterly estimates

(DKKm)	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24e
Sales	42,031	41,265	45,566	48,092	53,367	54,300	58,731	65,863	65,349	68,060	71,311	82,342
<i>Growth, reported</i>	24.0%	24.5%	27.6%	26.4%	27.0%	31.6%	28.9%	37.0%	22.5%	25.3%	21.4%	25.0%
<i>Growth, local currency</i>	17.9%	14.7%	15.3%	17.6%	24.6%	35.9%	37.6%	42.9%	24.3%	24.9%	22.6%	24.5%
Key products												
Insulin	14,962	12,343	12,961	12,686	13,409	11,288	11,345	11,980	14,365	12,612	12,509	12,282
Ozempic	12,035	14,349	16,390	16,976	19,640	22,101	23,912	30,065	27,810	28,875	29,804	32,680
Rybelsus	2,063	2,172	3,011	4,053	4,356	3,988	4,496	5,910	5,013	5,918	5,453	6,960
Wegovy	1,404	1,181	1,157	2,446	4,563	7,518	9,648	9,614	9,377	11,659	17,304	22,622
Novoseven	2,271	2,018	2,108	1,911	2,101	1,794	2,078	1,985	1,952	1,802	2,003	1,922
Gross profit	35,114	35,196	38,366	39,830	45,185	46,444	49,018	55,849	55,433	57,786	60,003	69,912
<i>Gross margin</i>	83.5%	85.3%	84.2%	82.8%	84.7%	85.5%	83.5%	84.8%	84.8%	84.9%	84.1%	84.9%
OPEX	-16,359	-16,954	-18,242	-23,176	-20,211	-22,541	-22,203	-29,086	-23,019	-32,257	-26,080	-34,614
Sales & Distribution costs	-10,183	-10,840	-11,451	-13,743	-12,412	-14,342	-12,819	-17,170	-13,256	-14,934	-15,210	-21,187
<i>% of sales</i>	-24.2%	-26.3%	-25.1%	-28.6%	-23.3%	-26.4%	-21.8%	-26.1%	-20.3%	-21.9%	-21.3%	-25.7%
Research & Development costs	-5,206	-5,123	-5,633	-8,085	-6,728	-7,127	-8,128	-10,460	-8,606	-16,166	-9,488	-11,669
<i>% of sales</i>	-12.4%	-12.4%	-12.4%	-16.8%	-12.6%	-13.1%	-13.8%	-15.9%	-13.2%	-23.8%	-13.3%	-14.2%
Administrative costs	-970	-991	-1,158	-1,348	-1,071	-1,072	-1,256	-1,456	-1,157	-1,157	-1,382	-1,758
<i>% of sales</i>	-2.3%	-2.4%	-2.5%	-2.8%	-2.0%	-2.0%	-2.1%	-2.2%	-1.8%	-1.7%	-1.9%	-2.1%
EBIT	19,147	18,391	20,184	17,087	25,007	23,888	26,913	26,766	31,846	25,934	33,822	35,163
<i>EBIT margin</i>	45.6%	44.6%	44.3%	35.5%	46.9%	44.0%	45.8%	40.6%	48.7%	38.1%	47.4%	42.7%
Net profit	14,210	13,318	14,405	13,592	19,814	19,428	22,478	21,963	25,407	20,050	27,301	27,145

Source: ABG Sundal Collier

Income Statement (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Sales	111,696	111,831	119,853	126,946	140,800	176,954	232,261	287,053	349,514	394,371
COGS	-17,632	-17,617	-19,731	-20,932	-23,658	-28,448	-35,765	-43,919	-59,417	-65,071
Gross profit	94,064	94,214	100,122	106,014	117,142	148,506	196,496	243,134	290,097	329,300
Other operating items	-41,915	-43,041	-42,900	-46,135	-52,473	-66,335	-84,509	-99,146	-118,136	-133,889
EBITDA	52,149	51,173	57,222	59,879	64,669	82,171	111,987	143,988	171,961	195,411
Depreciation and amortisation	-2,987	-3,925	-4,679	-5,403	-5,452	-6,602	-7,999	-16,202	-19,727	-22,259
of which leasing depreciation	0	0	0	0	0	0	0	0	0	0
EBITA	49,162	47,248	52,543	54,476	59,217	75,569	103,988	127,786	152,234	173,152
EO Items	0	0	0	0	0	0	0	0	0	0
Impairment and PPA amortisation	-195	0	-982	-350	-573	-760	-1,414	-1,022	-1,244	-1,404
EBIT	48,967	47,248	51,561	54,126	58,644	74,809	102,574	126,765	150,990	171,749
Net financial items	-287	367	-3,930	-996	436	-5,747	2,100	-1,100	-3,300	-2,700
Pretax profit	48,680	47,615	47,631	53,130	59,080	69,062	104,674	125,665	147,690	169,049
Tax	-10,550	-8,987	-9,420	-10,992	-11,323	-13,537	-20,991	-25,761	-29,538	-33,810
Net profit	38,130	38,628	38,211	42,138	47,757	55,525	83,683	99,903	118,152	135,239
Minority interest	0	0	0	0	0	0	0	0	0	0
Net profit discontinued	0	0	0	0	0	0	0	0	0	0
Net profit to shareholders	38,130	38,628	38,211	42,138	47,757	55,525	83,683	99,903	118,152	135,239
EPS	15.39	15.93	16.09	18.05	20.79	24.51	18.67	22.42	26.51	30.59
EPS adj.	15.45	15.93	16.43	18.17	21.00	24.78	18.92	22.60	26.74	30.85
Total extraordinary items after tax	0	0	0	0	0	0	0	0	0	0
Leasing payments	0	0	0	0	0	0	0	0	0	0
Tax rate (%)	21.7	18.9	19.8	20.7	19.2	19.6	20.1	20.5	20.0	20.0
Gross margin (%)	84.2	84.2	83.5	83.5	83.2	83.9	84.6	84.7	83.0	83.5
EBITDA margin (%)	46.7	45.8	47.7	47.2	45.9	46.4	48.2	50.2	49.2	49.6
EBITA margin (%)	44.0	42.2	43.8	42.9	42.1	42.7	44.8	44.5	43.6	43.9
EBIT margin (%)	43.8	42.2	43.0	42.6	41.7	42.3	44.2	44.2	43.2	43.6
Pre-tax margin (%)	43.6	42.6	39.7	41.9	42.0	39.0	45.1	43.8	42.3	42.9
Net margin (%)	34.1	34.5	31.9	33.2	33.9	31.4	36.0	34.8	33.8	34.3
Growth Rates y-o-y	-	-	-	-	-	-	-	-	-	-
Sales growth (%)	-0.1	0.1	7.2	5.9	10.9	25.7	31.3	23.6	21.8	12.8
EBITDA growth (%)	1.0	-1.9	11.8	4.6	8.0	27.1	36.3	28.6	19.4	13.6
EBITA growth (%)	0.6	-3.9	11.2	3.7	8.7	27.6	37.6	22.9	19.1	13.7
EBIT growth (%)	1.1	-3.5	9.1	5.0	8.3	27.6	37.1	23.6	19.1	13.7
Net profit growth (%)	0.5	1.3	-1.1	10.3	13.3	16.3	50.7	19.4	18.3	14.5
EPS growth (%)	2.8	3.5	1.0	12.2	15.2	17.9	-23.8	20.1	18.3	15.4
Profitability	-	-	-	-	-	-	-	-	-	-
ROE (%)	80.2	76.0	69.8	69.7	71.2	72.0	88.1	82.2	71.2	63.1
ROE adj. (%)	80.6	76.0	71.6	70.3	72.1	73.0	89.6	83.0	71.9	63.7
ROCE (%)	93.0	85.6	82.0	76.1	67.9	68.4	81.6	67.3	56.3	56.0
ROCE adj. (%)	93.3	85.6	83.6	76.5	68.5	69.1	82.7	67.8	56.7	56.5
ROIC (%)	120.3	99.6	90.3	75.3	65.6	70.2	83.6	61.0	51.1	52.4
ROIC adj. (%)	120.3	99.6	90.3	75.3	65.6	70.2	83.6	61.0	51.1	52.4
Adj. earnings numbers	-	-	-	-	-	-	-	-	-	-
EBITDA adj.	52,149	51,173	57,222	59,879	64,669	82,171	111,987	143,988	171,961	195,411
EBITDA adj. margin (%)	46.7	45.8	47.7	47.2	45.9	46.4	48.2	50.2	49.2	49.6
EBITDA lease adj.	52,149	51,173	57,222	59,879	64,669	82,171	111,987	143,988	171,961	195,411
EBITDA lease adj. margin (%)	46.7	45.8	47.7	47.2	45.9	46.4	48.2	50.2	49.2	49.6
EBITA adj.	49,162	47,248	52,543	54,476	59,217	75,569	103,988	127,786	152,234	173,152
EBITA adj. margin (%)	44.0	42.2	43.8	42.9	42.1	42.7	44.8	44.5	43.6	43.9
EBIT adj.	49,162	47,248	52,543	54,476	59,217	75,569	103,988	127,786	152,234	173,152
EBIT adj. margin (%)	44.0	42.2	43.8	42.9	42.1	42.7	44.8	44.5	43.6	43.9
Pretax profit Adj.	48,875	47,615	48,613	53,480	59,653	69,822	106,088	126,686	148,934	170,452
Net profit Adj.	38,325	38,628	39,193	42,488	48,330	56,285	85,097	100,925	119,396	136,643
Net profit to shareholders adj.	38,325	38,628	39,193	42,488	48,330	56,285	85,097	100,925	119,396	136,643
Net adj. margin (%)	34.3	34.5	32.7	33.5	34.3	31.8	36.6	35.2	34.2	34.6

Source: ABG Sundal Collier, Company Data

Cash Flow (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
EBITDA	52,149	51,173	57,222	59,879	64,669	82,171	111,987	143,988	171,961	195,411
Net financial items	-287	367	-3,930	-996	436	-5,747	2,100	-1,100	-3,300	-2,700
Paid tax	-10,550	-8,987	-9,420	-10,992	-11,323	-13,537	-20,991	-25,761	-29,538	-33,810
Non-cash items	2,353	-1,555	2,139	2,216	-6,762	1,203	-1,463	0	0	0
Cash flow before change in WC	43,665	40,998	46,011	50,107	47,020	64,090	91,633	117,127	139,123	158,901
Change in working capital	-2,497	3,618	-151	1,844	7,980	14,797	17,275	6,823	2,126	5,560

Cash Flow (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Operating cash flow	41,168	44,616	45,860	51,951	55,000	78,887	108,908	123,949	141,249	164,462
Capex tangible fixed assets	-7,617	-9,623	-8,928	-5,818	-6,335	-12,146	-25,773	-45,000	-48,932	-51,268
Capex intangible fixed assets	-963	-2,825	-2,578	-16,618	-1,050	-2,776	-13,361	-15,000	-2,000	-2,000
Acquisitions and Disposals	0	368	-825	-950	-18,283	-7,075	0	-80,000	0	0
Free cash flow	32,588	32,536	33,529	28,565	29,332	56,890	69,774	-16,051	90,317	111,193
Dividend paid	-18,844	-19,048	-19,409	-20,121	-21,517	-25,303	-31,767	-49,952	-59,076	-67,619
Share issues and buybacks	-16,845	-15,567	-15,334	-16,855	-19,447	-24,086	-29,924	-20,000	0	-30,000
Leasing liability amortisation	0	0	0	0	0	0	0	0	0	0
Other non-cash items	623	-1,959	-3,853	-29	-3,231	-4,373	-8,203	0	-0	0
Balance Sheet (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Goodwill	0	0	0	0	4,346	5,092	4,464	4,464	4,464	4,464
Other intangible assets	3,325	5,145	5,835	20,657	38,825	46,324	55,942	68,086	67,008	65,771
Tangible fixed assets	35,247	41,891	50,551	50,269	55,362	66,671	90,961	201,593	232,633	263,476
Right-of-use asset	-	-	-	-	-	-	-	-	-	-
Total other fixed assets	3,703	4,666	5,929	7,513	10,113	14,770	22,043	22,043	22,043	22,043
Fixed assets	42,275	51,702	62,315	78,439	108,646	132,857	173,410	296,187	326,148	355,754
Inventories	15,373	16,336	17,641	18,536	19,621	24,388	31,811	34,446	41,942	41,409
Receivables	20,165	22,786	25,753	28,408	40,910	50,766	66,200	50,229	60,847	68,473
Other current assets	3,386	4,103	4,240	4,450	6,156	6,945	10,491	8,612	10,485	11,831
Cash and liquid assets	21,156	15,842	15,663	15,089	19,175	26,301	32,574	19,566	40,807	44,381
Total assets	102,355	110,769	125,612	144,922	194,508	241,257	314,486	409,040	480,229	521,848
Shareholders equity	49,815	51,839	57,593	63,325	70,746	83,486	106,561	136,513	195,589	233,208
Minority	0	0	-	-	-	-	-	-	-	-
Total equity	49,815	51,839	57,593	63,325	70,746	83,486	106,561	136,513	195,589	233,208
Long-term debt	0	0	3,009	2,897	12,961	24,318	20,528	10,000	10,000	10,000
Pension debt	1,336	1,256	1,334	1,399	1,280	762	742	742	742	742
Convertible debt	0	0	-	-	-	-	-	-	-	-
Leasing liability	0	0	0	0	0	0	0	0	0	0
Total other long-term liabilities	4,148	3,510	4,693	7,028	10,005	11,751	17,000	17,000	17,000	17,000
Short-term debt	5,936	5,125	5,686	11,372	17,342	8,557	13,594	97,116	87,116	77,116
Accounts payable	5,610	6,756	6,358	5,717	8,870	15,587	25,606	17,223	20,971	23,662
Other current liabilities	35,510	42,283	46,939	53,184	73,304	96,796	130,455	130,446	148,812	160,119
Total liabilities and equity	102,355	110,769	125,612	144,922	194,508	241,257	314,486	409,040	480,229	521,848
Net IB debt	-14,668	-9,992	-6,108	-3	11,883	7,009	1,880	87,882	56,641	43,067
Net IB debt excl. pension debt	-16,004	-11,248	-7,442	-1,402	10,603	6,247	1,138	87,140	55,899	42,325
Net IB debt excl. leasing	-14,668	-9,992	-6,108	-3	11,883	7,009	1,880	87,882	56,641	43,067
Capital employed	57,087	58,220	67,622	78,993	102,329	117,123	141,425	244,371	293,447	321,066
Capital invested	35,147	41,847	51,485	63,322	82,629	90,495	108,441	224,395	252,230	276,275
Working capital	-2,196	-5,814	-5,663	-7,507	-15,487	-30,284	-47,559	-54,382	-56,508	-62,069
EV breakdown	-	-	-	-	-	-	-	-	-	-
Market cap. diluted (m)	1,457,220	1,425,630	1,398,937	1,375,134	1,353,157	1,334,715	2,641,266	2,625,554	2,625,554	2,604,758
Net IB debt adj.	-14,668	-9,992	-6,108	-3	11,883	7,009	1,880	87,882	56,641	43,067
Market value of minority	0	0	0	0	0	0	0	0	0	0
Reversal of shares and participations	-978	-1,242	-1,334	-1,066	-916	-1,016	-1,253	-1,253	-1,253	-1,253
Reversal of conv. debt assumed equity	-	-	-	-	-	-	-	-	-	-
EV	1,441,574	1,414,396	1,391,495	1,374,065	1,364,124	1,340,708	2,641,893	2,712,183	2,680,942	2,646,573
Total assets turnover (%)	111.8	104.9	101.4	93.8	83.0	81.2	83.6	79.3	78.6	78.7
Working capital/sales (%)	-3.1	-3.6	-4.8	-5.2	-8.2	-12.9	-16.8	-17.8	-15.9	-15.0
Financial risk and debt service	-	-	-	-	-	-	-	-	-	-
Net debt/equity (%)	-29.4	-19.3	-10.6	-0.0	16.8	8.4	1.8	64.4	29.0	18.5
Net debt / market cap (%)	-1.0	-0.7	-0.4	-0.0	0.9	0.5	0.1	3.3	2.2	1.7
Equity ratio (%)	48.7	46.8	45.8	43.7	36.4	34.6	33.9	33.4	40.7	44.7
Net IB debt adj. / equity (%)	-29.4	-19.3	-10.6	-0.0	16.8	8.4	1.8	64.4	29.0	18.5
Current ratio	1.28	1.09	1.07	0.95	0.86	0.90	0.83	0.46	0.60	0.64
EBITDA/net interest	181.7	139.4	14.6	60.1	148.3	14.3	53.3	130.9	52.1	72.4
Net IB debt/EBITDA (x)	-0.3	-0.2	-0.1	-0.0	0.2	0.1	0.0	0.6	0.3	0.2
Net IB debt/EBITDA lease adj. (x)	-0.3	-0.2	-0.1	-0.0	0.2	0.1	0.0	0.6	0.3	0.2
Interest coverage	32.9	28.1	13.2	21.4	25.3	12.7	126.5	31.9	42.4	57.8

Source: ABG Sundal Collier, Company Data

Share Data (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Actual shares outstanding	2,473	2,420	2,374	2,334	2,297	2,265	4,483	4,456	4,456	4,421
Actual shares outstanding (avg)	2,473	2,420	2,374	2,334	2,297	2,265	4,483	4,456	4,456	4,421

Share Data (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
All additional shares	-57	-54	-45	-40	-37	-31	2,218	-27	0	-35
Issue month	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assumed dil. of shares from conv.	0	0	0	0	0	0	0	0	0	0
As. dil. of shares from conv. (avg)	5	5	0	0	0	0	0	0	0	0
Conv. debt not assumed as equity	0	0	0	0	0	0	0	0	0	0
No. of warrants	0	0	0	0	0	0	0	0	0	0
Market value per warrant	0	0	0	0	0	0	0	0	0	0
Dilution from warrants	0	0	0	0	0	0	0	0	0	0
Issue factor	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Actual dividend per share	7.70	8.02	8.47	9.22	11.02	14.02	11.14	13.26	15.17	0.00
Reported earnings per share	-	-	-	-	-	-	-	-	-	-

Source: ABG Sundal Collier, Company Data

Valuation and Ratios (DKKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Shares outstanding adj.	2,473	2,420	2,374	2,334	2,297	2,265	4,483	4,456	4,456	4,421
Diluted shares adj.	2,473	2,420	2,374	2,334	2,297	2,265	4,483	4,456	4,456	4,421
EPS	15.39	15.93	16.09	18.05	20.79	24.51	18.67	22.42	26.51	30.59
Dividend per share	7.70	8.02	8.47	9.22	11.02	14.02	11.14	13.26	15.17	0.00
EPS adj.	15.45	15.93	16.43	18.17	21.00	24.78	18.92	22.60	26.74	30.85
BVPS	20.10	21.38	24.26	27.13	30.80	36.85	23.77	30.63	43.89	52.75
BVPS adj.	18.76	19.26	21.80	18.28	12.01	14.16	10.30	14.35	27.85	36.86
Net IB debt/share	-5.92	-4.12	-2.57	-0.00	5.17	3.09	0.42	19.72	12.71	9.74
Share price	589.20	589.20	589.20	589.20	589.20	589.20	589.20	589.20	589.20	589.20
Market cap. (m)	1,457,220	1,425,630	1,398,937	1,375,134	1,353,157	1,334,715	2,641,266	2,625,554	2,625,554	2,604,758
Valuation	-	-	-	-	-	-	-	-	-	-
P/E (x)	38.3	37.0	36.6	32.6	28.3	24.0	31.6	26.3	22.2	19.3
EV/sales (x)	12.91	12.65	11.61	10.82	9.69	7.58	11.37	9.45	7.67	6.71
EV/EBITDA (x)	27.6	27.6	24.3	22.9	21.1	16.3	23.6	18.8	15.6	13.5
EV/EBITA (x)	29.3	29.9	26.5	25.2	23.0	17.7	25.4	21.2	17.6	15.3
EV/EBIT (x)	29.4	29.9	27.0	25.4	23.3	17.9	25.8	21.4	17.8	15.4
Dividend yield (%)	1.3	1.4	1.4	1.6	1.9	2.4	1.9	2.3	2.6	0.0
FCF yield (%)	2.2	2.3	2.4	2.1	2.2	4.3	2.6	-0.6	3.4	4.3
Le. adj. FCF yld. (%)	2.2	2.3	2.4	2.1	2.2	4.3	2.6	-0.6	3.4	4.3
P/BVPS (x)	29.31	27.56	24.29	21.72	19.13	15.99	24.79	19.23	13.42	11.17
P/BVPS adj. (x)	29.99	28.20	24.81	22.20	20.91	17.78	26.77	21.35	14.36	11.77
P/E adj. (x)	38.1	37.0	35.9	32.4	28.1	23.8	31.1	26.1	22.0	19.1
EV/EBITDA adj. (x)	27.6	27.6	24.3	22.9	21.1	16.3	23.6	18.8	15.6	13.5
EV/EBITA adj. (x)	29.3	29.9	26.5	25.2	23.0	17.7	25.4	21.2	17.6	15.3
EV/EBIT adj. (x)	29.3	29.9	26.5	25.2	23.0	17.7	25.4	21.2	17.6	15.3
EV/CE (x)	25.3	24.3	20.6	17.4	13.3	11.4	18.7	11.1	9.1	8.2
Investment ratios	-	-	-	-	-	-	-	-	-	-
Capex/sales (%)	7.7	11.1	9.6	17.7	5.2	8.4	16.8	20.9	14.6	13.5
Capex/depreciation	2.9	3.2	2.5	4.2	1.4	2.3	4.9	3.7	2.6	2.4
Capex tangibles / tangible fixed assets	21.6	23.0	17.7	11.6	11.4	18.2	28.3	22.3	21.0	19.5
Capex intangibles / definite intangibles	78.3	219.5	213.4	1,197.3	62.7	83.4	390.4	165.1	24.2	27.0
Depreciation on intang / def. intang	19	78	40	79	64	48	54	20	22	25
Depreciation on tangibles / tangibles	7.82	6.98	8.29	8.57	7.92	7.50	6.78	7.13	7.69	7.75

Source: ABG Sundal Collier, Company Data

Analyst Certification

We, ABGSC Healthcare Research and Morten Larsen, analyst(s) with ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited (hereinafter collectively referred to as “ABG Sundal Collier”), and the author(s) of this report, certify that notwithstanding the existence of any such potential conflicts of interests referred to below, the views expressed in this report accurately reflect my/our personal view about the companies and securities covered in this report. I/We further certify that I/We has/have not been, nor am/are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

This report is produced by ABG Sundal Collier, which may cover companies either in accordance with legal requirements designed to promote the independence of investment research (“independent research”) or as commissioned research. Commissioned research is paid for by the subject company. As such, commissioned research is deemed to constitute an acceptable minor non-monetary benefit (i.e., not investment research) as defined in MiFID II.

Stock ratings distribution

ABG Sundal Collier Ratings and Investment Banking by 12/23/2024

Total of Rating	Research Coverage	Investment Banking Clients (IBC)	
	% of Total Rating	% of Total IBC	% of Total Rating by Type
BUY	65.23%	17%	7.02%
HOLD	29.65%	4%	3.64%
SELL	4.31%	0%	0.00%

IBC: Companies in respect of which ABG SC or an affiliate has received compensation for investment banking services within the past 12 months.

Analyst stock ratings definitions

BUY = We expect this stock’s total return to exceed the market’s expected total return by 5% or more over the next six months.

HOLD = We expect this stock’s total return to be in line with the market’s expected total return within a range of 4% over the next six months.

SELL = We expect this stock’s total return to underperform the market’s expected total return by 5% or more over the next six months.

Analyst valuation methods

When setting the individual ratings for investment research (“independent research”), ABG Sundal Collier assumes that a normal total absolute return (including dividends) for the market is 8% per annum, or 4% on a 6-month basis. Therefore, when we rate a stock a BUY, we expect an absolute return of 9% or better over six months. Volatility and low trading volumes mean that we have a wider range for expected returns on small cap stocks than for large caps.

ABG Sundal Collier’s analysts publish price targets for independent research and may publish valuation ranges for commissioned research. These price targets or valuation ranges rely on various valuation methods. One of the most frequently used methods is the valuation of a company by calculation of that company’s discounted cash flow (DCF). Another valuation method is the analysis of a company’s return on capital employed relative to its cost of capital. Finally, the analysts may analyse various valuation multiples (e.g., the P/E multiples and the EV/EBITDA multiples) relative to global industry peers. In special cases, particularly for property companies and investment companies, the ratio of price to net asset value is considered. Price targets and valuation ranges are changed when earnings and cash flow forecasts are changed. They may also be changed when the underlying value of a company’s assets changes (in the cases of investment companies, real estate companies or insurance companies) or when factors impacting the required rate of return change.

Expected updates

ABGSC has no fixed schedule for updating its research reports. Unless expressly stated otherwise, ABGSC expects (but does not undertake) to issue updates when considered necessary by the research department, for example following the publication of new figures or forecasts by a company or in the event of any material news on a company or its industry.

Stock price, company ratings and target price history

Company: Novo Nordisk


Currency: DKK

Current Recommendation: BUY

Date: 20/12/2024

Current Target price: 1,000.0

Current Share price: 589.20



Important Company Specific Disclosure

The following disclosures relate to the relationship between ABG Sundal Collier and its affiliates and the companies covered by ABG Sundal Collier referred to in this research report.

Unless disclosed in this section, neither ABG Sundal Collier nor any of their affiliated or associated companies and their directors, officers, representatives, and employees have any required regulatory disclosures to make in relation to an ownership position for the analyst(s) and members of the analyst's household, ownership by ABG Sundal Collier and/or its affiliates, ownership in ABG Sundal Collier Holding ASA by the company(ies) to whom the recommendation(s) refer(s) to, liquidity provision/market making agreement, managed or co-managed public offerings, compensation for provision of certain services, directorship of the analyst, or a member of the analyst's household, or in relation to any contractual obligations to the issuance of this research report.

ABG Sundal Collier is not aware of any other actual, material conflicts of interest of the analyst or ABG Sundal Collier of which the analyst knows or has reason to know at the time of the publication of this report.

Production of recommendation: 12/23/2024 06:03.

All prices are as of market close on 20 December, 2024 unless otherwise noted.

For full details of recommendation and target price history for the subject company, please see company page on Research Web.

For details of recommendations and target prices for ABG Sundal Collier coverage universe, please see coverage page on ABG Sundal Collier's Research Web.

Disclaimer

This report has been prepared by ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited and any of their directors, officers, representatives and employees (hereinafter collectively referred to as "ABG Sundal Collier"). This report is not a product of any other affiliated or associated companies of any of the above entities.

This report is provided solely for the information and use of professional investors, who are expected to make their own investment decisions without undue reliance on this report. The information contained herein does not apply to, and should not be relied upon by, retail clients. This report is for distribution only under such circumstances as may be permitted by applicable law. Research reports prepared by ABG Sundal Collier are for information purposes only. The recommendation(s) in this report is (are) has/ have no regard to specific investment objectives and the financial situation or needs of any specific recipient. ABG Sundal Collier and/or its affiliates accepts no liability whatsoever for any losses arising from any use of this report or its contents. This report is not to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but ABG Sundal Collier and/or its affiliates make no representation as to its accuracy or completeness and it should not be relied upon as such. All opinions and estimates herein reflect the judgment of ABG Sundal Collier on the date of this report and are subject to change without notice. Past performance is not indicative of future results.

The compensation of our research analysts is determined exclusively by research management and senior management, but not including investment banking management. Compensation is not based on specific investment banking revenues, however, it is determined from the profitability of the ABG Sundal Collier group, which includes earnings from investment banking operations and other business. Investors should assume that ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge and/or ABG Sundal Collier AB is seeking or will seek investment banking or other business relationships with the companies in this report.

The research analyst(s) responsible for the preparation of this report may interact with trading desk and sales personnel and other departments for the purpose of gathering, synthesizing and interpreting market information. From time to time, ABG Sundal Collier and/or its affiliates and any shareholders, directors, officers, or employees thereof may (I) have a position in, or otherwise be interested in, any securities directly or indirectly connected to the subject of this report, or (II) perform investment banking or other services for, or solicit investment banking or other services from, a company mentioned in this report. ABG Sundal Collier and/or its affiliates rely on information barriers to control the flow of information contained in one or more areas of ABG Sundal Collier, into other areas, units, groups or affiliates of ABG Sundal Collier.

Norway: ABG Sundal Collier ASA is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet)

Denmark: ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet) and the Danish Financial Supervisory Authority (Finanstilsynet)

Sweden: ABG Sundal Collier AB is regulated by the Swedish Financial Supervisory Authority (Finansinspektionen)

UK: This report is a communication made, or approved for communication in the UK, by ABG Sundal Collier Limited, authorised and regulated by the Financial Conduct Authority in the conduct of its business.

US: This report is being distributed in the United States (U.S.) in accordance with FINRA Rule 1220 by ABG Sundal Collier Inc., an SEC registered broker-dealer and a FINRA/SIPC member which accepts responsibility for its content and its compliance with FINRA Rule 2241. Research reports distributed in the U.S. are intended solely for "major U.S. institutional investors," and "U.S. institutional investors" as defined under Rule 15a-6 of the Securities Exchange Act of 1934 and any related interpretive guidance and no-action letters issued by the Staff of the U.S. Securities and Exchange Commission ("SEC") collectively ("SEC Rule 15a-6"). Each major U.S. institutional investor and U.S. institutional investor that receives a copy of this research report, by its acceptance of such report, represents that it agrees that it will not distribute this research report to any other person. This communication is only intended for major U.S. institutional investors and U.S. institutional investors. Any person which is not a major U.S. institutional investor, or a U.S. institutional investor as covered by SEC Rule 15a-6 must not rely on this communication. The delivery of this research report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. Any major U.S. institutional investor or U.S. institutional investor receiving this report which wishes to effect transactions in any securities referred to herein should contact ABG Sundal Collier Inc., not its affiliates. Further information on the securities referred to herein may be obtained from ABG Sundal Collier Inc., on request.

Singapore: This report is distributed in Singapore by ABG Sundal Collier Pte. Ltd, which is not licensed under the Financial Advisors Act (Chapter 110 of Singapore). In Singapore, this report may only be distributed to institutional investors as defined in Section 4A(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"), and should not be circulated to any other person in Singapore.

Canada: This report is being distributed by ABG Sundal Collier ASA in Canada pursuant to section 8.25 of National Instrument 31-103 or an equivalent provision and has not been tailored to the needs of any specific investor in Canada. The information contained in this report is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering or an offer to sell the securities described herein, in Canada or any province or territory thereof. No securities commission or similar regulatory authority in Canada has reviewed or considered this report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Under no circumstances is this report to be construed as an offer to sell such securities or as a solicitation of an offer to buy such securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada may only be made in accordance with applicable securities laws and only by a dealer properly registered under such securities laws, or alternatively, pursuant to an applicable dealer registration exemption, in the Canadian jurisdiction in which such offer or sale is made.

This report may not be reproduced, distributed, or published by any recipient for any purpose whatsoever without the prior written express permission of ABG Sundal Collier.

Additional information available upon request. If reference is made in this report to other companies and ABG Sundal Collier provides research coverage for those companies, details regarding disclosures may be found on our website www.abgsc.com.

© Copyright 2024 ABG Sundal Collier ASA

Norway	Sweden	Denmark	United Kingdom	USA	Germany	Singapore
Ruseløkkveien 26, 8th floor 0251 Oslo	Regeringsgatan 25, 8th floor	Forbindelsesvej 12, 2100 Copenhagen	10 Paternoster Row, 5th floor	140 Broadway, Suite 4604 New York, NY 10005	Schillerstrasse 2, 5. OG 60313 Frankfurt	10 Collyer Quay Ocean Financial Center
Norway	111 53 Stockholm	Denmark	London EC4M 7EJ	USA	Germany	#40-07, Singapore 049315
Tel: +47 22 01 60 00	Sweden	Tel: +45 35 46 61 00	UK	Tel. +1 212 605 3800	Tel +49 69 96 86 96 0	Tel +65 6808 6082
Fax: +47 22 01 60 60	Tel: +46 8 566 286 00	Fax: +45 35 46 61 10	Tel: +44 20 7905 5600	Fax. +1 212 605 3801	Fax +49 69 96 86 96 99	
	Fax: +46 8 566 286 01		Fax: +44 20 7905 5601			